To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
Study Type
OBSERVATIONAL
Enrollment
374
Investigator assessment of improvement in the clinical picture of the course on a 6-point symptoms profile
Time frame: Up to 4 weeks after first study drug administration
Investigator assessment of efficacy on a 4-point scale
Time frame: Up to 4 weeks after first study drug administration
Investigator assessment of tolerability on a 4-point scale
Time frame: Up to 4 weeks after first study drug administration
Number of patients with adverse drug reactions
Time frame: Up to 4 weeks after first study drug administration
Number of patients who withdrew from the study
Time frame: Up to 4 weeks after first study drug administration
Number of patients who changed the concomitant medication
Time frame: Up to 4 weeks after first study drug administration
Number of patients who continued the treatment
Time frame: Up to 4 weeks after first study drug administration
Patient assessment of efficacy on a 4-point scale
Time frame: Up to 4 weeks after first study drug administration
Patient assessment of tolerability on a 4-point scale
Time frame: Up to 4 weeks after first study drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.